Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 219

1.

Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration.

Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland ML, Tarp U, van Riel PL, Nordström DC, Gomez-Reino J, Pavelka K, Tomsic M, Kvien TK, van Vollenhoven RF, Gabay C.

Ann Rheum Dis. 2012 Mar;71(3):374-7. doi: 10.1136/annrheumdis-2011-200003. Epub 2011 Oct 4.

PMID:
21972242
2.

Comparative effectiveness of rituximab in combination with either methotrexate or leflunomide in the treatment of rheumatoid arthritis.

Narváez J, Díaz-Torné C, Ruiz JM, Hernández MV, Torrente-Segarra V, Ros S, Rodriguez de la Serna A, Díaz-López C, Sanmartí R, Nolla JM.

Semin Arthritis Rheum. 2011 Dec;41(3):401-5. doi: 10.1016/j.semarthrit.2011.06.005. Epub 2011 Aug 20.

PMID:
21862107
3.

Comparative effectiveness of tumour necrosis factor alpha inhibitors in combination with either methotrexate or leflunomide.

Strangfeld A, Hierse F, Kekow J, von Hinueber U, Tony HP, Dockhorn R, Listing J, Zink A.

Ann Rheum Dis. 2009 Dec;68(12):1856-62. doi: 10.1136/ard.2008.098467. Epub 2009 Jan 6.

PMID:
19126559
4.
5.

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.

Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T.

N Engl J Med. 2004 Jun 17;350(25):2572-81.

6.

Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group.

Cohen S, Cannon GW, Schiff M, Weaver A, Fox R, Olsen N, Furst D, Sharp J, Moreland L, Caldwell J, Kaine J, Strand V.

Arthritis Rheum. 2001 Sep;44(9):1984-92.

7.

[Leflunomide as a second choice treatment in patients with rheumatoid arthritis].

Raczkiewicz-Papierska A, Dudek A, Bachta A, Tłustochowicz M, Zawadyl B, Sułek M.

Pol Merkur Lekarski. 2007 Jun;22(132):547-50. Polish.

PMID:
17874627
8.

Leflunomide, a new disease-modifying drug for treating active rheumatoid arthritis in methotrexate-controlled phase II clinical trial.

Bao C, Chen S, Gu Y, Lao Z, Ni L, Yu Q, Xu J, Li X, Liu J, Sun L, He P, Ma J, Xu S, Ding C.

Chin Med J (Engl). 2003 Aug;116(8):1228-34.

PMID:
12935395
9.

Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries.

Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland ML, Tarp U, Gabay C, van Riel PL, Nordström DC, Gomez-Reino J, Pavelka K, Tomsic M, Kvien TK, van Vollenhoven RF.

Ann Rheum Dis. 2011 Sep;70(9):1575-80. doi: 10.1136/ard.2010.148759. Epub 2011 May 12.

PMID:
21571731
10.

Effect of rituximab on physical function and quality of life in patients with rheumatoid arthritis previously untreated with methotrexate.

Rigby W, Ferraccioli G, Greenwald M, Zazueta-Montiel B, Fleischmann R, Wassenberg S, Ogale S, Armstrong G, Jahreis A, Burke L, Mela C, Chen A.

Arthritis Care Res (Hoboken). 2011 May;63(5):711-20. doi: 10.1002/acr.20419.

11.

Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden.

Geborek P, Crnkic M, Petersson IF, Saxne T; South Swedish Arthritis Treatment Group.

Ann Rheum Dis. 2002 Sep;61(9):793-8.

12.

Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group.

Strand V, Cohen S, Schiff M, Weaver A, Fleischmann R, Cannon G, Fox R, Moreland L, Olsen N, Furst D, Caldwell J, Kaine J, Sharp J, Hurley F, Loew-Friedrich I.

Arch Intern Med. 1999 Nov 22;159(21):2542-50.

PMID:
10573044
13.

The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial.

Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, Racewicz AJ, van Vollenhoven RF, Li NF, Agarwal S, Hessey EW, Shaw TM; DANCER Study Group.

Arthritis Rheum. 2006 May;54(5):1390-400.

14.

Rituximab pharmacokinetics in patients with rheumatoid arthritis: B-cell levels do not correlate with clinical response.

Breedveld F, Agarwal S, Yin M, Ren S, Li NF, Shaw TM, Davies BE.

J Clin Pharmacol. 2007 Sep;47(9):1119-28.

PMID:
17766699
15.
16.

Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial.

Kremer JM, Genovese MC, Cannon GW, Caldwell JR, Cush JJ, Furst DE, Luggen ME, Keystone E, Weisman MH, Bensen WM, Kaine JL, Ruderman EM, Coleman P, Curtis DL, Kopp EJ, Kantor SM, Waltuck J, Lindsley HB, Markenson JA, Strand V, Crawford B, Fernando I, Simpson K, Bathon JM.

Ann Intern Med. 2002 Nov 5;137(9):726-33.

PMID:
12416946
17.

Methotrexate versus leflunomide in rheumatoid arthritis: what is new in 2011?

Singer O, Gibofsky A.

Curr Opin Rheumatol. 2011 May;23(3):288-92. doi: 10.1097/BOR.0b013e328344f2e4. Review.

PMID:
21378570
18.

Rituximab and concomitant leflunomide for the treatment of rheumatoid arthritis.

Henes JC, Schedel J, Kanz L, Koetter I.

Rheumatol Int. 2010 Mar;30(5):709-12. doi: 10.1007/s00296-009-1302-z. Epub 2009 Dec 12.

PMID:
20012622
19.

Update 2011: leflunomide in rheumatoid arthritis - strengths and weaknesses.

Behrens F, Koehm M, Burkhardt H.

Curr Opin Rheumatol. 2011 May;23(3):282-7. doi: 10.1097/BOR.0b013e328344fddb. Review.

PMID:
21427581

Supplemental Content

Support Center